Showing results 1 to 20 of 55
next >
| Issue Date | Title | Author(s) |
| 2014-01-01 | Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations | Haghi, M; Ong, HX; Traini, D; Young, P |
| 2020-11 | An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. | Sheikh, Z; Bradbury, P; Pozzoli, M; Young, PM; Ong, HX; Traini, D |
| 2016-02-15 | Antibiotic transport across bronchial epithelial cells: Effects of molecular weight, LogP and apparent permeability | Stigliani, M; Haghi, M; Russo, P; Young, PM; Traini, D |
| 2016-10-01 | Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products | Pozzoli, M; Ong, HX; Morgan, L; Sukkar, M; Traini, D; Young, PM; Sonvico, F |
| 2010-08-01 | Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products | Strusi, OL; Barata, P; Traini, D; Young, PM; Mercuri, S; Colombo, G; Sonvico, F; Bettini, R; Colombo, P |
| 2011-01 | Cellular release profiling of controlled release dry powder pulmonary formulation | Ong, HX; Traini, D; Bebawy, M; Young, P; Dalby, RN; Byron, PR; Peart, J; Suman, JD; Young, PM |
| 2015-06-01 | CHARACTERIZATION OF A COMMERCIAL NASAL POWDER DRUG DELIVERY DEVICE | Pozzoli, M; Sonvico, F; Zhu, B; Rogueda, P; Traini, D; Young, P |
| 2010-01 | Characterization of P-gp Expression and Function vs. Time and Passage in the Calu-3 Air-Interface Model for Drug Delivery to the Lung | Haghi, M; Young, P; Traini, D; Bebawy, M; Dalby, RN; Byron, PR; Peart, J; Suman, JD; Farr, SJ; Young, PM |
| 2011-09-01 | Chronic obstructive pulmonary disease: Patho-physiology, current methods of treatment and the potential for simvastatin in disease management | Marin, L; Colombo, P; Bebawy, M; Young, PM; Traini, D |
| 2013-06-01 | Ciprofloxacin is actively transported across bronchial lung epithelial cells using a calu-3 air interface cell model | Ong, HX; Traini, D; Bebawy, M; Young, PM |
| 2016-03-30 | Combination of Silver Nanoparticles and Curcumin Nanoparticles for Enhanced Anti-biofilm Activities | Loo, CY; Rohanizadeh, R; Young, PM; Traini, D; Cavaliere, R; Whitchurch, CB; Lee, WH |
| 2014-08 | COMBINATION THERAPY OF CURCUMIN AND SILVER NANOPARTICLES WITH ENHANCED ANTI-BIOFILM ACTIVITY FOR TREATMENT OF ENDOTRACHEAL TUBE-ASSOCIATED INFECTIONS | Loo, C-Y; Young, PM; Lee, W-H; Traini, D; Cavaliere, R; Whitchurch, CB; Rohanizadeh, R |
| 2011-01 | Comparison of albuterol sulphate and base dry powder particulate deposition using the Calu-3 lung epithelial model | Haghi, M; Traini, D; Bebawy, M; Young, P; Dalby, RN; Byron, PR; Peart, J; Suman, JD; Young, PM |
| 2015-06-01 | CURCUMIN AND SILVER NANOPARTICLE HYDROGELS FOR ENDOTRACHEAL TUBE-ASSOCIATED INFECTIONS: CHARACTERIZATION AND ANTI-BIOFILM ACTIVITIES | Loo, J; Lee, W-H; Young, PM; Traini, D; Cavaliere, R; Whitchurch, CB; Rohanizadeh, R |
| 2012-06-04 | Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia | Haghi, M; Traini, D; Bebawy, M; Young, PM |
| 2021-03-01 | Development and in vitro characterization of a novel pMDI diclofenac formulation as an inhalable anti-inflammatory therapy for cystic fibrosis. | Sheikh, Z; Gomes Dos Reis, L; Bradbury, P; Meneguzzo, G; Scalia, S; Young, PM; Ong, HX; Traini, D |
| 2017-09-02 | Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery | Pozzoli, M; Traini, D; Young, PM; Sukkar, MB; Sonvico, F |
| 2015-06-01 | Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection | Arora, S; Haghi, M; Loo, CY; Traini, D; Young, PM; Jain, S |
| 2018-08-25 | Development of ciprofloxacin-loaded poly(vinyl alcohol) dry powder formulations for lung delivery | Silva, DM; Paleco, R; Traini, D; Sencadas, V |
| 2016-10-02 | Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation | Pozzoli, M; Rogueda, P; Zhu, B; Smith, T; Young, PM; Traini, D; Sonvico, F |
